GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the shot.
The UK drugmaker will look at the data of 1.4 million people aged 65 to 66 years, some of whom received GSK’s Shingrix shot and some who did not, over a four-year period starting from 2023.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.